Maintenance Venetoclax in AML Fit Patients

this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.

Trial Details

NCT ID
NCT07244367
Phase
NA
Sponsor
Sohag University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • SC cytarabine +Venetoclax
Locations (sample)
  • Sohag, Egypt|26.55695,31.69478
  • Sohag, Egypt|26.55695,31.69478

Key Eligibility Criteria

  • Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →